EUCTR2010-022207-22-PL
进行中（未招募）
不适用
A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to one or more TNF-a Inhibitors (FLEX-V)
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- Rheumatoid Arthritis
- 发起方
- Eli Lilly and Company
- 入组人数
- 555
- 状态
- 进行中（未招募）
- 最后更新
- 14年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Patients will be male and female aged \=18 years of age with a diagnosis of moderately to severely active adult onset RA
- •Diagnosis of Rheumatoid Arthritis (RA) of more than 6 months and less than 15 years
- •At least 8 tender and swollen joints
- •An abnormally high C\-reactive protein (CRP) level or erythrocyte sedimentation rate (ESR)
- •Positive for Rheumatoid Factor (RF) or Anti\-cyclic citrullinated peptide (CCP) antibody
- •Previously treated with biologic TNF\-a inhibitor therapy (infliximab, certolizumab, golimumab, etanercept, adalimumab) and stopped treatment due to insufficient efficacy or intolerance
- •Regular use of at least one conventional disease\-modifying anti\-rheumatic drug (DMARD), with a stable dose for at least 8 weeks prior to study start
- •Woman must not be pregnant, breastfeeding, or become pregnant during the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
排除标准
- •Use of unstable doses of non\-steroidal inflammatory drugs (NSAIDS) in the past 6 weeks
- •Steroid injection or intravenous (IV) infusion in the last 6 weeks
- •Use of more than 10 mg/day of oral steroids in the last 6 weeks
- •History of a serious reaction to other biological DMARDs
- •Use of an oral calcineurin inhibitor (e.g., cyclosporin or tacrolimus) in the last 8 weeks
- •Surgery on a joint or other major surgery less than 2 months ago, or plans to have joint surgery or major surgery during the study
- •Active fibromyalgia, juvenile chronic arthritis, spondyloarthropathy, Crohn's disease, ulcerative colitis, psoriatic arthritis, or other systemic inflammatory condition except RA
- •Cervical cancer or squamous skin cancer within the past 3 years, or other cancer within the past 5 years
- •Received a live vaccine received within the past 12 weeks (for example, vaccines for measles, mumps, rubella, and chicken pox, and nasal\-spray flu vaccines)
- •Hepatitis or human immunodeficiency virus (HIV)
结局指标
主要结局
未指定
相似试验
进行中（未招募）
1 期
A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTD.Frontotemporal Dementia.MedDRA version: 21.1Level: PTClassification code 10068968Term: Frontotemporal dementiaSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2019-004066-18-ITAlector Inc.180
进行中（未招募）
1 期
A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTD followed by An Open-Label Study to Evaluate Long-Term Safety and Tolerability of AL001 in FTD.Frontotemporal DementiaMedDRA version: 21.1Level: PTClassification code 10068968Term: Frontotemporal dementiaSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2019-004066-18-DEAlector Inc.110
进行中（未招募）
1 期
A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTDFrontotemporal DementiaMedDRA version: 21.1Level: PTClassification code 10068968Term: Frontotemporal dementiaSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2019-004066-18-NLAlector Inc.180
进行中（未招募）
不适用
A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to one or more TNF-a InhibitorsRheumatoid ArthritisMedDRA version: 12.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2010-022207-22-GREli Lilly and Company555
进行中（未招募）
1 期
A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTDEUCTR2019-004066-18-FRAlector Inc.180